Table 2

CIs RSE cumulative probability to observe at least one AEI by week associated with a probability of occurrence of event of 1%

WeekExpected
population medically followed by the enrolled practices
Cumulative vaccine coverage after 14 weeks (%)Cumulative no of vaccinated subjectsCumulative no of subjects reported ≥1
AEIs
Average proportion of AEI reported (%)Lower
95% CL (%)
Upper
95% CL (%)
Cumulative
probability to observe at least one event (%)
Associated RSE (%)
150 0002071471.000.42.099.3737.2
250 000201 428141.000.51.6100.0026.3
350 000202 142211.000.61.5100.0021.5
450 000202 857281.000.71.4100.0018.6
550 000203 571351.000.71.4100.0016.7
650 000204 285421.000.71.3100.0015.2
750 000205 000501.000.71.3100.0014.1
850 000205 714571.000.81.3100.0013.2
950 000206 428641.000.81.3100.0012.4
1050 000207 142711.000.81.3100.0011.8
1150 000207 857781.000.81.2100.0011.2
1250 000208 571851.000.81.2100.0010.7
1350 000209 285921.000.81.2100.0010.3
1450 0002010 0001001.000.81.2100.009.9
150 0001035731.000.22.487.2652.7
250 0001071471.000.42.099.3737.2
350 000101 071101.000.41.799.9830.4
450 000101 428141.000.51.61000026.3
550 000101 785171.000.61.5100.0023.6
650 000102 142211.000.61.5100.0021.5
750 000102 500251.000.61.5100.0019.9
850 000102 857281.000.71.4100.0018.6
950 000103 214321.000.71.4100.0017.6
1050 000103 571351.000.71.4100.0016.7
1150 000103 928391.000.71.4100.0015.9
1250 000104 285421.000.71.3100.0015.2
1350 000104 642461.000.71.3100.0014.6
1450 000105 000501.000.71.3100.0014.1
150 000517811.000.03.153.2474.6
250 000535731.000.22.487.2652.7
350 000553551.000.32.297.0443.0
450 000571471.000.42.099.3737.2
550 000589281.000.41.899.8733.3
650 00051 071101.000.41.799.9830.4
750 00051 250121.000.51.7100.0028.1
850 00051 428141.000.51.6100.0026.3
950 00051 607161.000.61.6100.0024.8
1050 00051 785171.000.61.5100.0023.6
1150 00051 964191.000.61.5100.0022.5
1250 00052 142211.000.61.5100.0021.5
1350 00052 321231.000.61.5100.0020.7
1450 00052 500251.000.61.5100.0019.9
  • AEI, adverse event of interest; RSE, relative SE.